Effectiveness of Radiofrequency Combined With Ultrasound for the Treatment of Postpartum Dyspareunia

ConditionDyspareunia
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18-50
SponsorInstitut Investigacio Sanitaria Pere Virgili

About this trial

The objective of this community-based, non-randomized, quasi-experimental study is to assess the effectiveness of BTL EXILIS technology-based on combined radiofrequency and ultrasound-in women of childbearing age from an industrialized country with a diagnosis of dyspareunia following vaginal delivery.

The primary research question is:

\- Do patients experience a resolution of pain during sexual intercourse after completing the treatment?

The researcher will compare the level of pain during intercourse-following at least one vaginal delivery involving a tear or episiotomy-before and after exposure to the BTL Exilis treatment in the same individual.

Participants:

* Assessment following childbirth with perineal involvement (tear or episiotomy) and presenting with dyspareunia. * Verification of fulfillment of inclusion criteria. * Decision on whether to undergo treatment, following a briefing by the researcher on the process and the signing of the informed consent form for study participation. * Follow-up assessment one and a half months after completing the treatment.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Women of childbearing age

Medical history of at least one prior vaginal delivery

Reported persistent pain during penetrative sexual intercourse

Meeting the clinical criteria for dyspareunia

Disqualifiers

Contraindications to the study treatment. Women with any medical condition that precludes the use of the study technology

Non-postpartum dyspareunia

Trial design

Design model

Single group

Treatments tested in this trial

  • Combining radiofrequency and ultrasound. BTL Exilis

    Device

    Following the first session, participants will wait 4-6 weeks before undergoing the second session. Four to six weeks after the second session, a new medical history (anamnesis) will be taken to re-evaluate and quantify the perceived pain during intercourse using the Visual Analogue Scale (VAS). If the score is equal to or greater than 4, an immediate third session will be offered. Four to six weeks after the third session of BTL EXILIS Ultra 360º (Ultrafemme version), if required, pain during intercourse will be assessed once more for a third quantification; this figure will be recorded as the final VAS score following the treatment.

Treatment groups

34 Participants
are divided into 1 treatment group
Group A: Women with dyspareuniaExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Change in pain Intensity During Sexual Intercourse

Pain intensity measured using the Visual Analogue Scale (VAS), where 0 indicates "no pain" and 10 indicates "the worst pain imaginable". A higher score represents greater pain intensity

Time frame
Baseline, and at the end of the 1st, 2nd, and 3rd treatment sessions (approximately 12 weeks)

Secondary outcomes

1

Obstetric History: Parity

Total number of previous deliveries (parity) to evaluate its correlation with baseline dyspareunia severity

Time frame
Baseline (Day 1)
2

Time Since Last Delivery

Number of months elapsed from the last childbirth to the diagnosis of dyspareunia

Time frame
Baseline (Day 1)
3

History of Prior Deliveries (Years)

Recording the specific years of the first, second, and third deliveries to establish the patient's reproductive timeline

Time frame
Baseline (Day 1)
4

Presence of Perineal Scarring

Assessment of the presence or absence of perineal scars (categorical: Yes/No) resulting from previous deliveries (e.g., episiotomy or tears)

Time frame
Baseline (Day 1)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.